Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 5:35:100326.
doi: 10.1016/j.tipsro.2025.100326. eCollection 2025 Sep.

Pelvic stereotactic ablative body radiotherapy (SABR) reirradiation: UK SABR consortium guidance for use in routine clinical care

Elena Moreno-Olmedo  1   2 , Kasia Owczarczyk  1   3 , Eliot Chadwick  4 , Peter Dickinson  1   5 , Aileen Duffton  6 , Bleddyn Jones  7 , James S Good  1   8 , Fiona McDonald  9   10 , Louise J Murray  5   11 , Thomas Rackley  12 , Maxwell Robinson  2 , Judith Sinclair  13 , Thomas Strawson-Smith  14 , Alison Tree  9   10 , Yat Man Tsang  15 , Anjali Zarkar  8 , Christopher Dean  16 , Patricia Díez  17 , Matt Williams  18   19 , Nicholas Andratschke  20 , Rebecca Muirhead  2
Affiliations

Pelvic stereotactic ablative body radiotherapy (SABR) reirradiation: UK SABR consortium guidance for use in routine clinical care

Elena Moreno-Olmedo et al. Tech Innov Patient Support Radiat Oncol. .

Abstract

Stereotactic ablative body radiotherapy (SABR) is routinely used for the management of oligometastatic disease. Increasingly, there is overlap of targets or organs at risk with previous radiotherapy fields. As substantial variation in delivery of clinical practice exists, the UK SABR Consortium worked with a collaborative national group to develop pelvic SABR re-irradiation consensus guidelines. The scope of the guidance includes patient selection criteria, pre-treatment considerations, delineation guidelines, dose prescription, calculations of cumulative dose constraints, and optimal planning technique. This guidance is part of an ongoing national prospective audit in collaboration with the Royal College of Radiologists and EORTC ReCare.

Keywords: Guidance; Reirradiation; SABR; SBRT; Stereotactic radiotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Dr Tree also declares research funding from Elekta®, Varian® and Accuray® and honoraria or travel assistance from Elekta®, Accuray® and Janssen®. Dr. Tree is the Chair of the MR linac consortium.

Figures

Fig. 1
Fig. 1
Steps required for departmental and individual full accreditation to be approved to deliver SABR in NHS England.
Fig. 2
Fig. 2
Isotoxic plan to limited to prescription dose of 35 Gy in 5 fractions by small bowel and lumbosacral plexus. (GTV = magenta; Small bowel = yellow; Lumbosacral plexus = green).
See this image and copyright information in PMC

References

    1. https://www.england.nhs.uk/publication/clinical-commissioning-policy-ste... [Internet]. 2021 [cited 2025 Mar 19]. NHS England. Clinical Commissioning Policy: stereotactic ablative radiotherapy (SABR) for patients with previously irradiated, locally recurrent primary pelvic tumours (all ages) 202Available from: https://www.england.nhs.uk/publication/clinical-commissioning-policy-ste....
    1. Phillips R., Shi W.Y., Deek M., Radwan N., Lim S.J., Antonarakis E.S., et al. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: the ORIOLE phase 2 Randomized Clinical Trial. JAMA Oncol. 2020;6(5):650. - PMC - PubMed
    1. Ost P., Reynders D., Decaestecker K., Fonteyne V., Lumen N., De Bruycker A., et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): Five-year results of a randomized phase II trial. J Clin Oncol. 2020 Feb 20;38(6_suppl):10–10.
    1. Johnstone P., Okonta L., Aitken K., Holmes J., Harrison M., Harji D., et al. A multicentre retrospective review of SABR reirradiation in rectal cancer recurrence. Radiother Oncol. 2021;162:1–6. - PubMed
    1. Glynne-Jones R., Wyrwicz L., Tiret E., Brown G., Rödel C., Cervantes A., et al. Rectal cancer: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28 - PubMed

LinkOut - more resources